Concepedia

Author

P H de Mulder

Radboud University Nijmegen

Also Known As

P H De Mulder, P H de Mulder, P. H. De Mulder, P.H. De Mulder, Pieter H De Mulder, Pieter H. De Mulder, Pieter H. de Mulder, Pieter HM de Mulder

22

Publications

1K

Citations

14

H-Index

33

Concepts

All Affiliations

Radboud University NijmegenRadboud University Medical CenterKantonsspital St. GallenInstitut Gustave RoussyRotterdam University of Applied Sciences
PH

About

P H de Mulder is an author at Radboud University Nijmegen specializing in medicine, oncology, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

295

2

Immunology

6

6

226

3

Health Sciences

1

1

31

4

Cell Biology

1

1

18

5

Gastroenterology

1

1

29

P H de Mulder

×

14

Publications

993

Citations

13

H-Index

YearCitations

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

A. Horwich, D.Th. Sleijfer, Sophie D. Fosså,

Journal of Clinical Oncology

1997

331

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

Sophie D. Fosså, Stuart Kaye, Graham M. Mead,

Journal of Clinical Oncology

1998

145

Vaccination of Patients With Metastatic Renal Cell Carcinoma With Autologous Dendritic Cells Pulsed With Autologous Tumor Antigens in Combination With Interleukin-2: A Phase 1 Study

Jeannette Oosterwijk‐Wakka, Dorien M. Tiemessen, Ivar Bleumer,

Journal of Immunotherapy

2002

99

Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the Locoregional Lymph Nodes

Carla M. van Herpen, Maaike W.G. Looman, Marijke I. Zonneveld,

Clinical Cancer Research

2004

87

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication

Wim H.J. Kruit, K. Punt, S.H. Goey,

Cancer

1994

55

Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.

Carla M. van Herpen, Richard Huijbens, Maaike W.G. Looman,

PubMed

2003

50

Clinical and Immunopathological Results of a Phase II Study of Perilymphatically Injected Recombinant Interleukin-2 in Locally Far Advanced, Nonpretreated Head and Neck Squamous Cell Carcinoma

Vera Mattijssen, P H de Mulder, Jan H. Schornagel,

Journal of Immunotherapy

1991

45

A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)

P H de Mulder, Jan Roigas, Silke Gillessen,

Journal of Clinical Oncology

2006

38

Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC): Updated results

Sandhya Srinivas, Jan Roigas, Silke Gillessen,

Journal of Clinical Oncology

2007

31

Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma

Vera Mattijssen, P H de Mulder, Alexander de Graeff,

Annals of Oncology

1994

30

Page 1